| Literature DB >> 11790727 |
Reinhard Hiller1, Sylvia Laffer, Christian Harwanegg, Martin Huber, Wolfgang M Schmidt, Anna Twardosz, Bianca Barletta, Wolf M Becker, Kurt Blaser, Heimo Breiteneder, Martin Chapman, Reto Crameri, Michael Duchêne, Fatima Ferreira, Helmut Fiebig, Karin Hoffmann-Sommergruber, Te Piao King, Tamara Kleber-Janke, Viswanath P Kurup, Samuel B Lehrer, Jonas Lidholm, Ulrich Müller, Carlo Pini, Gerald Reese, Otto Scheiner, Annika Scheynius, Horng-Der Shen, Susanne Spitzauer, Roland Suck, Ines Swoboda, Wayne Thomas, Raffaela Tinghino, Marianne Van Hage-Hamsten, Tuomas Virtanen, Dietrich Kraft, Manfred W Müller, Rudolf Valenta.
Abstract
Type I allergy is an immunoglobulin E (IgE)-mediated hypersensitivity disease affecting more than 25% of the population. Currently, diagnosis of allergy is performed by provocation testing and IgE serology using allergen extracts. This process defines allergen-containing sources but cannot identify the disease-eliciting allergenic molecules. We have applied microarray technology to develop a miniaturized allergy test containing 94 purified allergen molecules that represent the most common allergen sources. The allergen microarray allows the determination and monitoring of allergic patients' IgE reactivity profiles to large numbers of disease-causing allergens by using single measurements and minute amounts of serum. This method may change established practice in allergy diagnosis, prevention, and therapy. In addition, microarrayed antigens may be applied to the diagnosis of autoimmune and infectious diseases.Entities:
Mesh:
Substances:
Year: 2002 PMID: 11790727 DOI: 10.1096/fj.01-0711fje
Source DB: PubMed Journal: FASEB J ISSN: 0892-6638 Impact factor: 5.191